SCHEMBL4970352

SCHEMBL4970352

Cc1ccc(NC(=O)c2cc(F)cnc2Cl)cc1F

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNQ3 O43525 2/20 0.54
KCNQ2 O43526 2/20 0.54
KCNE1 P15382 2/20 0.54
KCNQ1 P51787 2/20 0.54
KCNQ5 Q9NR82 1/20 0.53
ALDH1A1 P00352 2/20 0.50
HSD17B10 Q99714 1/20 0.50
RAB9A P51151 5/20 0.49
NPC1 O15118 4/20 0.49
SMN1; SMN2 Q16637 3/20 0.48
KDM4E B2RXH2 2/20 0.47
POLB P06746 3/20 0.47
TP53 P04637 3/20 0.47
LMNA P02545 3/20 0.47
GLA P06280 1/20 0.47
HPGD P15428 1/20 0.47
HTT P42858 1/20 0.47
ATM Q13315 1/20 0.47
MAPT P10636 1/20 0.46
KDR P35968 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4968123 0.90 RAB9A (0.56) ALDH1A1HSD17B10RAB9ANPC1SMN1; SMN2
SCHEMBL4966413 0.85 BRAF (0.47) KCNQ3KCNQ2KCNE1KCNQ1SMN1; SMN2
SCHEMBL4971162 0.85 RAB9A (0.51) ALDH1A1HSD17B10RAB9ANPC1SMN1; SMN2
SCHEMBL4968741 0.83 RAB9A (0.45) KCNQ3KCNQ2KCNE1KCNQ1ALDH1A1
SCHEMBL4968696 0.82 KCNQ3 (0.56) KCNQ3KCNQ2KCNE1KCNQ1
SCHEMBL4970824 0.82 P2RX1 (0.54) ALDH1A1RAB9ANPC1SMN1; SMN2LMNA
SCHEMBL4967762 0.81 SMN1; SMN2 (0.53) ALDH1A1RAB9ANPC1SMN1; SMN2POLB
SCHEMBL4967520 0.80 RAB9A (0.53) KCNQ3KCNQ2KCNE1KCNQ1ALDH1A1
SCHEMBL4966677 0.80 RAB9A (0.51) RAB9ANPC1SMN1; SMN2HTTMAPT
SCHEMBL4966684 0.78 NFKB1 (0.58) KCNQ3KCNQ2KCNE1KCNQ1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8247556-B2 Method for preparing 6-substituted-7-aza-indoles AMGEN INC. (US) 2012-08-21 US disclosed
EP-1971604-B1 PYRROLO-PYRIDINE DERIVATIVES FOR THE TREATMENT OF CANCER DISEASES AMGEN INC (US) 2012-08-01 EP disclosed
EP-1971604-A2 PYRROLO-PYRIDINE DERIVATIVES FOR THE TREATMENT OF CANCER DISEASES Amgen Inc. (US) 2008-09-24 EP disclosed
US-20070185171-A1 Compounds and methods of use AMGEN INC. 2007-08-09 US disclosed
WO-2007048070-A2 PYRROLO-PYRIDINE DERIVATIVES FOR THE TREATMENT OF CANCER DISEASES AMGEN INC. (US) 2007-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070185171-A1 Compounds and methods of use VHL, PGF, PTGIS KCNQ3 3613/4885KCNQ2 3979/4885KCNE1 3966/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.